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The number of allogeneic hematopoietic stem cell (HSC) transplants performed globally each year continues
to increase. Advances in HLA typing, better supportive care, and administration of reduced-intensity condi-
tioning regimens allow treatment of older patients with older sibling donors. Pretransplant donor assessment
and testing are very important processes affecting the quality and safety of donation. For unrelated HSC
donors detailed recommendations for health assessment have been published, allowing donation only if they
are unrestrictedly healthy. Eligibility criteria for related donors are less strict and vary signiﬁcantly between
centers. In situations where a family donor does not meet the suitability criteria for unrelated donors,
involved physicians often struggle with the decision whether the matched relative is suitable for donation or
not. On behalf of the Worldwide Network for Blood and Marrow Transplantation Standing Committee onedgments on page 2059.
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N. Worel et al. / Biol Blood Marrow Transplant 21 (2015) 2052e2060 2053Donor Issues, we intended to develop a consensus document with recommendations for donor workup and
ﬁnal clearance of family donors who would not be able to serve as unrelated donors because of their age or
pre-existing diseases. This article covers different topics intending to support decision-making, with the goal
of minimizing medical risk to the donor and protection of the recipient from transmissible diseases.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION WBMT took place in Vienna in September 2013. The purpose of this work-
Over the last years the total number of allogeneic he-
matopoietic stem cell transplantations (HSCTs) performed
annually has exceeded 30,000 a year. The observed contin-
uous annual increase of around 10% is mainly because of a
rise in allogeneic HSCT from unrelated stem cell donors
(URDs) [1,2]. In 2013 the proportion of URDs was 53% in
centers reporting to the European Group for Blood and
Marrow Transplantation (EBMT) [3], and the stem cell source
preferably used was granulocyte colony-stimulating factor
(G-CSF)-mobilized peripheral blood stem cells (PBSCs) in 73%
of HSCTs [2]. Furthermore, the number of donor lymphocyte
infusions has also been increasing. Advances in HLA typing,
the use of new immunosuppressive protocols, better sup-
portive care, and the administration of reduced-intensity
conditioning regimens contribute to the increased fre-
quency of HSCT and allow treatment of older patients whose
related donors usually are also older [4,5].
Pretransplant donor assessment and testing are very
important issues affecting the quality and safety of donation.
Several international regulatory bodies (eg, European Di-
rectives for Donation of Tissues and Cellular Therapy Prod-
ucts, US Food and Drug Administration) have detailed
requirements on donor evaluation to ensure the safety of the
product for the recipient but do not address donor safety
issues. For HSC URDs, the World Marrow Donor Association
(WMDA) has published detailed recommendations for donor
assessment [6] and a donor suitability tool [7] open access
ﬁle reﬂecting WMDA recommendations to ensure donor and
recipient safety as well as the quality of the cellular product.
In addition, the Worldwide Network for Blood and Marrow
Transplantation (WBMT) has established a consensus state-
ment for a standardized assessment of donor outcome data
[8]. Donor eligibility criteria for related donors [9], who still
comprise almost half of all donors, are less strict than for
URDs [6], with few deﬁnite criteria and signiﬁcant variation
between HSCT centers. URDs are only eligible if they are
unrestrictedly healthy, most often very similar to eligibility
criteria for blood donation. Further differences between
related donors and URDs may exist in mobilization and
collection practices [8,10-12]. Published data suggest that the
risks for serious adverse events and reactions might be
higher for related donors than for URDs, but the amount of
adequate prospective data in the related setting is still
limited [13,14].
Involved physicians often struggle with the decision
about whether a related donor not meeting suitability
criteria for an URD can be regarded suitable for donation in
the related HSCT setting. This article intends to give recom-
mendations to support decision-making, with the goal of
minimizing medical risk to the donor and protection of the
recipient from transmissible diseases.
METHODS
On behalf of the WBMT Standing Committee on Donor Issues, a work-
shop with international representatives (Supplementary Table 1) involved
in related and/or unrelated HSC donation from various member societies ofshop was to develop a consensus document with recommendations for
donor workup and ﬁnal clearance of family donors whowould not be able to
serve as an URD because of their age (<18 or >60 years) or pre-existing
diseases. In preparation for this workshop, different sections regarding or-
gan system assessment, medical conditions, and pediatric donation were
deﬁned and assigned to experts in the ﬁeld who served as group leaders for
the particular sections (Supplementary Table 1). Groupmembers performed
a thorough review of the literature presented at theworkshop and came to a
consensus on recommendations for standardized related donor screening.
Sources of information included English-language articles extracted
from PubMed (www.ncbi.nlm.nih.gov/pubmed) published until May 31,
2013, focusing on clinical studies of HSC mobilization and donation,
guidelines for preoperative cardiac risk assessment and perioperative car-
diac management in noncardiac surgery [15], and G-CSF application for
other conditions than HSC mobilization [16], and the UK, Canadian, Italian,
National MarrowDonor Program [17] andWMDA [18] recommendations for
evaluation of URD were provided. In addition, group leaders received the
S(P)EAR (Serious (Product) Events and Adverse Reactions) Committee
Annual Report from 2011 provided by the WMDA (http://www.worldmarro
w.org/ﬁleadmin/Committees/SEAR/PRES/20110707-CLWG-SEAR_Sum-
mary_2003-2010.pdf) and the report of NOTIFY, a global consultation
organized by the Italian National Transplant Centre and the European
Unionefunded Project “Vigilance and Surveillance of Substances of Human
Origin” exploring vigilance notiﬁcation for organs, tissues, and cells (pub-
lished in February 2011; http://www.notifylibrary.org/sites/default/ﬁles/
BOOK%20NOTIFY.pdf).
A consensus was achieved that a classiﬁcation system for evaluating the
physical status of a donor would be very useful to enable assessment by
independent physicians or respective specialists for donors with disorders
(eg, cardiologists, dermatologists, rheumatologists) who should preferably
have knowledge of PBSC mobilization and/or PBSC and bone marrow (BM)
donation modalities. Especially for related donor evaluation assigned to BM
donation, the implementation of the American Society of Anesthesiologists
Physical Status (ASA-PS) classiﬁcation system [19] was discussed as a
possibly useful tool because it records only the individual’s preoperative
physical status rather than the surgical risk. The ASA system consists of 5
categories that classify individuals according to the severity of their systemic
disease and is used worldwide by anesthesia providers [20] (Supplementary
Table 2).
The term “disorders” expresses all medical conditions that may affect
the safety and efﬁcacy of donation. The participants agreed that the term
“generally not recommended” instead of “deferral” should be used to
categorize certain medical conditions in the related donor setting.RESULTS
General Considerations
During the process of donor selection and evaluation, the
following general considerations need to be taken into
account.
1. A 10/10 HLA-identical URD should be preferred to a
related donor with health disorders exposing himself or
herself or the recipient to a higher risk for adverse events
as described in the entire article. For many diseases
outcome after URD transplantation is comparable with
HSCT with related donors [21]. For these situations an
URD if available should be preferred to a related donor
with health disorders.
2. Suitability might be assessed also in donors below and
above the age limits for URD. No strict chronological age
limit can be recommended for related donors, but
experience is available up to a donor age of 75 years.
However, physicians assessing the donor’s suitability
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disorders increases with age. Transplant physicians
should pay attention to the fact that collection yield as
well as graft composition in older donors might be
different from young donors [22,23]. In addition,
number of CD34þ cells in peripheral blood and CD34þ
yield in apheresis products reportedly are lower in
older donors [24], and apheresis complications have
been more frequently observed [25].
3. A related donor not meeting donor eligibility criteria for
URD might be considered suitable for HSC donation after
careful assessment of both the donor’s and recipient’s
risk, including consideration of alternative therapies for
the recipient. Although maximum donor safety is a
mainstay in URD HSC collection, related donors are
oftenwilling to accept higher risks associated with the
donation procedure to help their family members.
Indeed, personal experience of the workshop partici-
pants as well as a recent publication [26] suggest that
beyond the strict suitability and eligibility criteria for
URDs, there is a gray area where related donors might
donate safely. Furthermore, some disorders lead to
donor deferral because of a risk for transmission of a
(most often infectious) disease to the recipient. How-
ever, transplant physicians and recipients might be
willing to accept a certain risk for disease transmission
to treat another, more serious, life-threatening malig-
nant disease in a given patient.
4. Providers responsible for donor care should not be
involved in recipient’s care. Standards of the National
Marrow Donor Program [17] and the WMDA [18] state
that the medical evaluation of an URD must be per-
formed by a physician who is not a member of the
HSCT team caring for the patient, and participants of
the workshop believed this should be mandatory also
for related donors. This is even more important in
situations that leave room to physician’s discretion to
decide on donor suitability. However, this issue is not
yet mandatory according to standards of the Founda-
tion for the Accreditation of Cellular TherapyeJoint
Accreditation Committee of the International Society
for Cellular Therapy and European Group for Blood and
Marrow Transplantation [27].
5. Donor selection and health assessment should be started
early and be efﬁcient to provide a sound basis for decision
on donor suitability considering risks for donors and re-
cipients. Efforts should be undertaken to prevent any
delay of HSCT (eg, due to delayed start of an URD search).
Early in the related donor evaluation process, donor
medical assessment may be performed before HLA
tissue typing by a limited questionnaire to assess
donor ﬁtness and willingness to donate. For investi-
gation of health disorders, disease specialists should be
consulted at an early stage of donor workup if appro-
priate. Based on these results, risk assessment should
be made considering all factors that increase risk for
donor health and increase risk for recipient health
compared with the risk associated with an HSCT from
an URD.
In case of an increased risk for the donor, this indi-
vidual should be informed thoroughly by a separate
evaluator who serves only the donor’s interests (cf.
consideration 3). The donor must be able to decide for
or against donation without coercion. In case ofincreased risk for the recipient, the HSCT center and
recipient shall be informed and must decide whether
to accept or decline the donor. This raises issues about
informing the recipient of donor medical conditions
the donor may not wish to share. Detailed
information-sharing about medical conditions from
the donor to family members must be at the discretion
of the potential donor. If a donor is ineligible for
medical reasons, the only information that should be
shared with the transplant physician (or the recipient
and the family) is the statement that the donor is
ineligible for donationwithout communicating further
details (eg, HIV). If a donor is not willing to donate, the
information given should be the same. In case of a
medical condition that may allow an HSCT but is
associated with an increased risk for the recipient (eg,
hepatitis B virus infection), the donor has to give
informed consent for transmission of the information;
otherwise, the donor would be ineligible.
6. The informed consent process plays a central role in
donor assessment. The fact that donor and recipient know
each other and are in an emotional relationship needs to
be considered carefully. All individuals should fully
understand the donation process and give their
informed consent to the process and to the testing of
their blood and other medical exams for diseases that
may affect the suitability of their HSCs. Furthermore,
donors have to give separate informed consent for
transmission of information about health issues that
may affect the recipient’s health. Third-party in-
terpreters must understand the requirements of the
national and local regulations relevant to the donation
process and not be personally known to the potential
donor or recipient.
7. Registration in a donor outcome database is needed to
improve our knowledge on risk assessment for HSC
donation. The intent of this article’s recommendations
is to support decision-making, acknowledging that
these are mainly expert opinions that need to be vali-
dated in the future. For this reason, as well as to meet
the World Health Organization guiding principles on
human cell tissue and organ transplantation [28],
donor outcome data need to be prospectively collected
and analyzed in registries.
A summary of conditions, suitability, and individuals at
risk is given in Supplementary Table 3.
Suitability Criteria in Pulmonary Diseases
Asthma
Donor suitability is dependent on disease severity and its
control. Individuals are suitable if symptoms are controlled
with topical treatment, whereas HSC donation is generally
not recommended in subjects dependent on oral cortico-
steroids because of disease exacerbation. In the case of an
acute exacerbation requiring i.v. or oral corticosteroids and/
or emergency care/hospitalization, individuals are tempo-
rally unsuitable. If possible, corticosteroid administration
should be completed within 7 days before HSC donation
because corticosteroid therapy canmask signs of infection. In
donors classiﬁed as >ASA P2, PBSC donation might be
considered to avoid intubation during general anesthesia for
BM harvest. Individuals with exercise-induced asthma are
suitable.
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HSC donation is generally not recommended for in-
dividuals with a history of repeated attacks of coughing or
dyspnea at rest to avoid further deterioration of pulmonary
function, because there is evidence that administration of G-
CSF is associated with signiﬁcant gas exchange disturbance
resolving on discontinuation of the drug [29]. Individuals
with cystic ﬁbrosis can be suitable depending on their pul-
monary function tests. BM donation requiring intubation is
generally not recommended in donors classiﬁed as >ASA P2.
Suitability Criteria in Gastrointestinal Disorders
For gastroesophageal reﬂux, peptic ulcer disease, celiac
disease, and irritable bowel syndrome, individuals are suit-
able if no active bleeding is detected and they are stable
under treatment with only mild impact on daily living. After
an episode of diverticulitis/diverticulosis, individuals are
suitable if they have completely recovered. In ongoing or
poorly controlled situations, HSC donation is generally not
recommended.
Suitability Criteria for Noninfectious Liver, Biliary Tract,
Spleen and Pancreatic Disorders
For hereditary hemochromatosis, donors are suitable if
they are ﬁt for blood donation and no organ dysfunction is
present (eg, cirrhosis, heart failure). In case of elevated liver
enzymes (not associated with infectious disease), the cause
should be assessed, and HSC donation is temporally not
recommended until a diagnosis has been clariﬁed. In-
dividuals with proven nonalcoholic fatty liver disease are
suitable. In Wilson’s disease, suitability depends on the dis-
ease stage. In subjects with symptomatic disease and organ
impairment (eg, Child-Pugh Score B and C), HSC donation is
generally not recommended. The latter is also the case for
individuals with liver cirrhosis or sclerosing cholangitis [30].
Individuals after splenectomy or with splenomegaly are
suitable depending on its cause. There is evidence that
spleen size increases during G-CSF administration by 11% to
13%, with splenic rupture as a known, but rare, complication.
Donors should be advised to avoid contact sports during
G-CSF application, HSC donation, and early thereafter. In
chronic pancreatitis the cause should be assessed, and in
severe organ impairment HSC donation is generally not
recommended.
Suitability Criteria for Kidney and Genitourinary Tract
Diseases
In cases of acute renal failure, HSC donation is generally
not recommended until recovery and after evaluation of
cause. In individuals with chronic renal failure, the cause
should be investigated, and donors might be suitable if there
are no other contraindications (eg, cardiovascular disease)
found. Individuals with a history of glomerulonephritis are
suitable if they have fully recovered (including normal urine
tests) from an acute infection and no residual kidney
impairment has been observed. In cases of chronic infection
or an association with systemic disease (eg, systemic lupus
erythematosus, diabetes mellitus [DM]) and/or recovery
with decreased kidney function (<30mL/min), HSC donation
is generally not recommended. There is evidence that G-CSF
may induce transient urinary protein excretion and macro-
scopic hematuria in HSC donors with IgA nephropathy
(Annelies Billen, personal communication, April 2014) or
pre-existing microscopic hematuria [31,32]. Based on this, it
would be reasonable that donors with a history of immune-mediated glomerulonephritis and abnormal urine tests
should preferably donate BM. Individuals with polycystic
kidney disease are suitable when they have normal kidney
function and normal blood pressure. The major extrarenal
complications of autosomal dominant polycystic kidney
disease include cerebral aneurysms, presence of cysts in
other organs, cardiac valve disease, colonic diverticula, and
aortic root dilatation. Therefore, cerebral aneurysms should
be excluded during medical workup.
In case of nephrectomy due to disease included in the list
of contraindications, HSC donation is generally not recom-
mended. If an individual has only one kidney because of
traumatic injury, kidney donation, or birth with a single
kidney, donation is suitable if fully recovered with normal
kidney function.
Suitability Criteria for Cardiovascular, Cerebrovascular,
and Peripheral Vascular Diseases
Because these disorders are more common in elderly in-
dividuals or ones afﬂicted by comorbidities, a thorough
evaluation of clinical risk factors has to be performed during
the medical workup to identify subjects at risk for devel-
oping peridonation cardiac problems and to allow medical
optimization of the condition to potentially improve donor’s
outcome. In addition to the ASA-PS classiﬁcation system,
clinical risk factors should be considered according to the
European Society of Anaesthesiology (ESA) [19,33] and
American College of Cardiology/American Heart Association
guidelines [34]. Clinical risk factors include a history of
ischemic myocardial disease, current stable, or a history of
heart failure and a history of cerebrovascular disease,
insulin-dependent DM, and renal failure. Cardiac conditions
that necessitate further evaluation and treatment include
unstable coronary syndromes, recent myocardial infarction
within 30 days, decompensated heart failure, signiﬁcant ar-
rhythmias, and severe valvular disease [33,35]. The ESA
guidelines state that cardiac risk but not age should be used
to trigger increased medical assessment and that the likeli-
hood of postoperative mortality and morbidity depends on
an individual’s background risk interacting with the grade of
intervention (level of evidence B) [33,35]. In the ESA and
European Society of Cardiology guidelines for preoperative
cardiac risk assessment in noncardiac surgery, a preoperative
cardiac risk stratiﬁcation according to the Lee index
including a history of ischemic heart and/or cerebrovascular
disease, heart failure, insulin-dependent DM, impaired renal
function, and high-risk type of surgery is recommended
(level of evidence A) [36]. Furthermore, measurements of
brain natriuretic peptide (BNP) and N-terminal proBNP (NT-
proBNP) could serve as biomarkers for cardiac impairment
(level of evidence B). Participants at the workshop agreed
that noncardiac surgery is comparable with BM and PBSC
donation and recommend the use of ASA-PS classiﬁcation
and European Society of Cardiology/ESA and American Col-
lege of Cardiology/American Heart Association guidelines for
predonation assessment by general medicine physicians and
specialists.
G-CSF has been used in a substantial number of patients
with acute myocardial infarction to improve regeneration
[16,37,38]. In a meta-analysis studying the efﬁcacy and safety
of G-CSF of 6 randomized trials with 320 patients, including
160 given G-CSF,16% and 19% of cardiac events were reported
in the G-CSF and the control group, respectively, including 2
deaths in each cohort. Of note, no increase in target-vessel
stenosis was observed in the G-CSF group [16]. The
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severe chronic ischemic heart disease suggests that fewer
CD34þ cells are mobilized by G-CSF compared with age-
matched control subjects; however, no increase in cardiac
site effects was observed [37,39-41].
Participants of the workshop recommend that a thorough
evaluation of clinical risk factors preferably by an indepen-
dent physician should be performed during the medical
check-up. In case of an active cardiac disease, thorough
evaluation by a cardiologist is required and cardiac risk
stratiﬁcation should be performed by a cardiologist or
anesthesiologist. Furthermore, existing comorbidities should
be evaluated during the medical check-up, including heart
failure, ischemic heart disease, transient ischemic attack or
stroke, renal failure, brain failure (dementia and delirium),
and peripheral arterial disease. A potential donor’s physical
ﬁtness and predonation risk score for BM or PBSC donation
should be assessed using criteria for noncardiac surgery. If a
donor is found to be suitable, a plan for peridonation treat-
ment and supportive care should be established before start
of the donation procedure.
Eligibility Criteria in Noninfectious Eye Diseases
Noninfectious inﬂammatory eye diseases (uveitis, iritis,
iridocyclitis, chorioretinitis, scleritis, conjunctivitis) can
occur as an isolated manifestation of an autoimmune disease
in association with systemic diseases (eg, arthritis, connec-
tive tissue diseases, Behçet disease), as a result of a trauma, or
as a side effect of medications. HSC donation is generally not
recommended during an acute inﬂammatory process
because uveitis has been reported as an adverse event after
G-CSF administration [42,43]. In the presence of systemic
disease suitability has to be assessed accordingly. A potential
transmission of autoimmune disease has to be considered
with the recipient before donation [44].
Glaucoma describes a group of ocular disorders leading to
intraocular pressure-associated optic neuropathy. In-
dividuals are suitable if glaucoma is well controlled and
stable and if an underlying disease does not exclude suit-
ability. Temporary deferral should be considered in newly
diagnosed or unstable situations until treatment is estab-
lished to avoid donor risk. Subjects with age-related macular
degeneration or retinitis pigmentosa, an inherited or spon-
taneously occurring degenerative eye disease, are considered
suitable. Eligibility of individuals with corneal grafts has
been addressed by many national and international regula-
tions and guidelines. Transmission of variant Creutzfeldt-
Jakob disease (vCJD) by infected cornea grafts has been
reported [45,46], and in theory transmission to the HSC
recipient might be possible if the donor has been exposed to
CJD by a corneal transplant before donation, although this
has not been reported to date. In view of the long latency
until manifestation of clinical disease [47], individual cases
should be decided by the HSCT center and the respective
recipient.
Suitability Criteria for Hematological Diseases and
Coagulation Disorders
In case of anemia the underlying cause should be eval-
uated. Subjects are eligible if anemia is mild (<2 g/dL below
lower limit of normal) or corrected unless the underlying
condition is a contraindication for HSC donation. PBSC
rather than BM collection might be considered to avoid
further RBC loss. Individuals with hemolytic anemia are
suitable if the disease has been infectious- or drug-inducedand they have fully recovered. HSC collections from in-
dividuals with RBC abnormalities such as spherocytosis and
elliptocytosis are generally not recommended, whereas
subjects with G6PD deﬁciency are eligible [48]. Individuals
with thalassemia trait, mild a-thalassemia, or b-thalassemia
minor are suitable, whereas donations in case of interme-
diate/major forms are generally not recommended. The
same holds true for sickle cell anemia. Subjects with sickle
cell b-thalassemia minor may be suitable for BM donation.
However, it is strongly recommended to avoid G-CSF in
donors with sickle cell b-thalassemia, sickle cell disease, or
other complex sickle hemoglobinopathies because this may
provoke severe sickle cell crisis [49,50].
Individuals with neutropenia or lymphocytopenia
without an underlying condition despite thorough medical
evaluation are suitable if cytopenia does not exceed less than
1.0  109 neutrophils/L or less than 0.5  109 lymphocytes/L
(expert opinion). It is not clear if an adequate mobilization
can be achieved in these conditions.
Individuals with leukocytosis and lymphocytosis are
suitable if no underlying condition known to be a contrain-
dication to donation is present. In individuals with mono-
clonal B cell lymphocytosis with conﬁrmed clonality, HSC
donation is generally not recommended. In individuals with
a persistent (>3 months) monoclonal paraproteinemia
detectable by protein electrophoresis, HSC donation is
generally not recommended.
HSC collections from individuals with platelet disorders
are generally not recommended if excessive bleeding or
bruising is to be expected or from individuals with excessive
thrombocytosis due to the potentially increased risk for
venous thromboembolism (VTE). Individuals with mild
thrombocytopenia (100 to 130  109/L) are suitable unless
the underlying condition is a contraindication for HSC
donation. Individuals with thrombocytopenia of unknown
origin or secondary immune thrombocytopenia (due to an
underlying disease or drug exposure) are suitable if the
disease has completely resolved. HSC donation is generally
not recommended if subjects are symptomatic or are less
than 6 months from recovery.
Individuals with a history of VTE are suitable if a speciﬁc
cause other than cancer has been identiﬁed and anticoagu-
lant therapy has already ceased. VTE prophylaxis needs to be
considered during the collection process. HSC donation is
generally not recommended in recurrent VTE (2 episodes in
12 months). Individuals with hereditary thrombophilia
without VTE, such as subjects with factor V Leiden, may be
suitable, but prophylaxis for VTE should be considered.
Subjects with bleeding diathesis (eg, vonWillebrand disease)
are suitable if the disease is mild and asymptomatic or well
controlled by replacement therapy. Donors with acquired
hemophilia and/or bleeding diathesis are considered ineli-
gible. Subjects with hemophilia are suitable if they are only
carriers or in case of factor XII deﬁciency. In all other cases of
hemophilia, donors may become suitable for donation after
adequate factor replacement.Suitability Criteria for Malignancies
Several studies describe the risk of donor-derived ma-
lignancy transmission in solid organ transplantation,
whereas no data exist for HSCT [9,51,52]. The main reason for
this is that almost all donors with a history for malignancy
are excluded from stem cell donation. This is also deﬁned in
several national and international legislations stating that all
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should not be considered for HSC.
In cases of a history of basal cell carcinoma or a carcinoma
in situ of the uterine cervix, responsible physicians need to
have written histological conﬁrmation to exclude invasive
disease and to avoid malignant disease transmission. How-
ever, if a donor is in remission from an invasive cancer for
more than 5 to 10 years, that donor could at least be
considered if no other donor is available. As guidance, risk
categories for donor tumor transmission in solid organ
transplantation could be used [51]. In case of intermediate
risk of tumor transmission, the use of this donor is generally
not recommended. On occasion, a lifesaving transplant may
be acceptable in circumstances where recipient expected
survival without transplantation is short. Informed consent
of the recipient should be required.Womenwithout a history
of cancer but with BRCA1/2 positivity and on antihormonal
medication for breast cancer prevention (tamoxifen/aroma-
tase inhibitors) are considered suitable if more than 4 weeks
have passed after the last dosage of medication.
Suitability Criteria for Immunodeﬁciencies and
Autoimmune Disorders
Currently, over 120 conditions associated with primary
immunodeﬁciencies are known [53]. Nearly all individuals
diagnosed with primary or acquired noninfectious immu-
nodeﬁciencies are permanently ineligible for HSC donation.
Subjects with recovered immunodeﬁciency proven by labo-
ratory test results may be eligible on an individual basis.
Individuals with selective IgA deﬁciency may be suitable to
donate if they are otherwise doing well.
For many autoimmune disorders adoptive transfer of
diseases from the donor to the recipient during allogeneic
HSCT has been documented [44,54,55], although it is
currently unclear whether these were transferred by donor
HSC, T cells, other cells, and/or antibodies [44,56]. Thus, in all
cases a careful risk-to-beneﬁt analysis has to be performed
for both the donor and the recipient. However, HSC donation
is generally not recommended in individuals with systemic
multiorgan involvement, including ankylosing spondylitis,
antiphospholipid, antibody syndrome, arteritis cranialis
(temporal arteritis), thromboangiitis obliterans (Buerger’s
disease), dermatomyositis, polymyositis, polymyalgia
rheumatic, multiple sclerosis/optic neuritis, systemic lupus
erythematosus, scleroderma, Sjögren’s syndrome, vasculitis
syndromes, Cogan’s syndrome, and Behçet’s disease, because
these diseases can be transmitted and have a severe impact
on a recipient’s quality of life, need for additional therapy,
and survival beyond the risks for the donor. Based on expert
opinion, participants of the workshop stated that in the
presence of any immunosuppressive medication other than
low-dose steroids (ie, 5 mg prednisolone/day), HSC dona-
tion is generally not recommended because these medica-
tions may increase a donor’s susceptibility for opportunistic
infections.
Of note, their impact on the recipient’s immune recon-
stitution and on risk for graft-versus-host disease is not
known yet. Therefore, the transplant physician and the
recipient should weigh the risk and beneﬁts on an individual
basis. Furthermore, the potential risk of disease ﬂare-up in
the donor mainly through administration of G-CSF [29,57,58]
but in rare cases also in BM donation should be taken into
consideration [59].
Single-organ autoimmune disease, including thyroid
disease (eg, Hashimoto thyroiditis, Graves’ disease),pernicious anemia, psoriasis, alopecia areata, and vitiligo
usually are not life-threatening, and individuals are often
otherwise medically ﬁt for HSCT donation. Subjects with
mild or moderate psoriasis requiring only topical treatments
are suitable when collection sites are unaffected. In thyroid
disease, thyroid dysfunction should be controlled and a state
of euthyroid function should be achieved before donation.
No data on donor suitability are available for HSC donation,
but in analogy to recommendations for pregnancy, donors
might be suitable at the earliest 6 months after radioiodine
therapy in relation to the complete clearance of radioiodine
from the body after therapy or 1 month after administration
of thyrostatic drugs, respectively [60]. PBSC donation is
feasible, because G-CSF treatment in patients with Graves’
disease and agranulocytosis after administration of thyro-
static drugs reportedly did not cause an exacerbation of the
underlying disease [61,62].
Individuals with DM type 1 are suitable if DM is
controlled and no evidence of late effects (eg, vasculopathy)
are present, leading to an increased risk for donation. In case
of active autoimmune hepatitis, HSC donation is generally
not recommended. Subjects are suitable if they are asymp-
tomatic and have not been under immunosuppressive
medication for at least 3 months. BM is the preferred source
of HSC [29,57,58].
Only in asymptomatic subjects with inﬂammatory bowel
disease (ulcerative colitis, Crohn’s disease) without signs of
inﬂammation and no immunosuppressive medication for at
least 3 months is HSC donation suitable. Because there is no
evidence that G-CSF worsens the symptoms of inﬂammatory
bowel disease [63,64], no preference for donation can be
stated.
Individuals with arthritis (rheumatoid, psoriatic, other
cause) are suitable if disease is mild and only requires
nonsteroidal anti-inﬂammatory drugs. To avoid G-CSF as a
trigger of joint inﬂammation, PBSC collection is not recom-
mended [65]. In addition, it has been shown that individuals
with severe rheumatoid arthritis mobilize signiﬁcantly less
CD34þ cells than healthy individuals [66].
Other Musculoskeletal Diseases
Subjects with asymptomatic osteoporosis are suitable for
PBSC or BM donation. In symptomatic individuals BM
donation is generally not recommended because of the
higher incidence of procedure-related side effects. In-
dividuals with a history of osteomyelitis are suitable if they
are cured and clearance of osteomyelitis is documented.
Subjects with mild/occasional back or spine pain are suitable
for PBSC donation if there is no underlying condition leading
to deferral. A history of current herniated or slipped disc,
severe/chronic pain, and of back surgery mandates PBSC
donation only. Individuals with scoliosis are suitable if no
functional impairment is detected. Subjects with muscular
dystrophy are suitable for PBSC donation if they are able to
tolerate the length of the procedure. Individuals with a his-
tory of malignant hyperthermia are suitable for PBSC dona-
tion only.
Suitability Criteria for Allergies and Allergic Reactions
Donors with allergies or anaphylactic reactions might be
suitable if the precipitating agent is known and preventive
actions ensure that donors will not be exposed to these
agents (eg, iodine, latex, lidocaine, acid-citrate-dextrose)
during PBSC or BM collection. The same is true for
IgE-mediated allergies, but because these can also be
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severe. If a previous allergic reaction to G-CSF has been
documented but the individual is otherwise healthy, he or
she is suitable for BM donation only. To avoid sequelae due to
allergic reaction in associationwith G-CSF, standards shall be
followed to ensure at least the ﬁrst G-CSF dose is adminis-
tered under medical supervision [18,27]. If an allergic reac-
tion occurs during the currently ongoing mobilization
process, the donor shall not receive further doses of G-CSF
but may be considered for BM collection if possible [67,68].Suitability Criteria for Endocrine and Metabolic Diseases
Individuals with well-controlled DM type 2 are suitable if
they do not have any late effects leading to an increased risk
for donation. In case of a history of gestational DM,
individuals are suitable after its resolution. DM type 1 is
covered above in Suitability Criteria for Immunodeﬁciencies
and Autoimmune Disorders. In individuals with gout, BM
should be considered the preferred HSC source to avoid acute
gouty arthritis due to G-CSF exposure [69]. Subjects with
hyperlipidemiawith or without treatment are only suitable if
they do not have symptomatic cardiovascular disease.
Obese subjects are generally suitable if body mass index
(BMI) in adults is 40. Centers should consider deferral of
individuals with BMI > 40 because these individuals are
known to experience higher rates of donation-related
adverse events [70]. Getting adequate venous access and/or
BM collection can be more challenging and anesthesia-
related risk increases (eg, ASA P3 for BMI > 40). Individuals
with Addison’s disease need to be evaluated for the cause of
adrenal insufﬁciency. If medical workup does not lead to a
deferral (eg, infections, amyloidosis, malignancies), asymp-
tomatic individuals on well-controlled replacement therapy
are suitable for HSC donation.
In subjects with a history of administration of human
pituitary-derived growth or gonadotropin hormones, the
HSCT center and the recipient shall be informed on the
possible risk for vCJD transmission. Suitability should be
assessed accordingly.Suitability Criteria for Neurological Disorders (Except
Cerebrovascular Disease)
Individuals with a history of meningitis/encephalitis are
suitable if they have fully recovered. If complement deﬁ-
ciency is the cause of (recurrent) meningitis, HSC donation is
generally not recommended. Subjects with epilepsy/seizures
are suitable if they are well controlled and are certiﬁed to
have the ﬁtness to drive (surrogate marker for well-
controlled seizures).
In cases of dementia or mentally disabled individuals,
careful attention should be paid to the ability of the indi-
vidual to understand the donation process and to give
informed consent to both the medical workup and the
collection procedure. Those unable to give appropriate con-
sent should be carefully considered in the light of possible
alternative URD. Mentally disabled individuals should be
treated similar to children, with an appropriate caregiver and
legal advocate helping to decide. During the workshop par-
ticipants suggested that in donors with mental disorders
stem cell harvest and cryopreservation should be considered
in advance before the conditioning regimen is started. In
cases of disabled subjects or ones with communication dif-
ﬁculties, their ability to consent should be assessed by a
special care physician.Individuals with migraine or Tourette’s syndrome are
suitable. For the latter, BM donation might be preferred as
motoric tics may cause difﬁculties in PBSC collection.
In cases of CJD, including sporadic, familial, and classic
type, donors are permanently deferred. In cases of ﬁrst-
degree relatives with CJD, family risk of CJD (>2 relatives
with CJD), history of dura mater graft, and use of human-
derived growth or human pituitary gonadotropin hormone,
HSC donation is generally not recommend. Different national
and international legislations need to be considered (cf.
corneal grafts). If legislations do not preclude donation, in-
dividual cases should be decided by the HSCT center and the
recipient.
Suitability Criteria for Psychological-Psychiatric
Disorders
Subjects with eating disorders (anorexia and/or bulimia)
are suitable if their disease is stable under appropriate
treatment and their BMI is >16.0 in adults. HSC donation in
individuals with multiple personality disorders and psy-
chosis is generally not recommended. Subjects with
obsessive-compulsive, attention deﬁcit, or attention deﬁcit
hyperactivity disorders are suitable if their disease is well
controlled. However, the donor’s capacity to follow through
the donation process may be affected. Individuals with un-
explained or chronic fatigue syndrome are only suitable if
they are asymptomatic or their symptoms do not affect ac-
tivities of daily life.
In case of substance abuse such as marijuana, individuals
are suitable but may require cessation of use before
donation/G-CSF injections. Subjects with a history of cocaine,
crack, and methamphetamine (intranasal/oral) abuse might
be suitable. Because methamphetamine use is associated
with an increased risk of cardiovascular pathologies, a careful
assessment is required. Individuals who are on a substitution
program but otherwise healthy are suitable. In cases of active
i.v. drug abuse, donation is generally not recommended. In all
individuals a careful history and medical assessment has to
be taken for risk factors for infectious diseases or underlying
psychiatric disorders. During the workshop participants
suggested that in donors with selected psychiatric disorders
(eg, anxiety, depression, and bipolar disorders) HSC harvest
and cryopreservation should be considered in advance
before the conditioning regimen is started.
Suitability Criteria for Pregnant and Breastfeeding
Women
HSC collection during pregnancy is not recommended.
Breastfeeding women are suitable for BM and PBSC donation,
but breastfeeding has to be temporarily paused from start of
the collection procedure (ie, start of anesthesia or ﬁrst dose
of G-CSF) by pumping and discarding breast milk post-
anesthesia or after the last dose of G-CSF for 24 hours and
then resuming to breastfeeding [71].
CONCLUSIONS
Allogeneic HSC donation is a safe procedure with very
low rates of serious adverse events [13]. However, new
developments in the treatment of hematological diseases
(eg, reduced-intensity conditioning, haploidentical trans-
plantation) confront us with a number of challenges like
elderly family donors or donors with comorbidities.
Although the WMDA has published detailed recommenda-
tions for the assessment of donor health [6], these recom-
mendations focus on URDs only.
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donors fall beyond the scope of eligibility and suitability
criteria for unrelated donation but still can safely donate cells
to save a life. This article of the WBMT Standing Committee
on Donor Issues is meant to give physicians some guidance
for decision-making. To improve our knowledge in the short
and long term, follow-up in all donors with prospective data
collection and analysis in large registries is absolutely vital in
the future [8,72] in this rapidly evolving ﬁeld to allow vigi-
lance and surveillance of donations and improve knowledge
of the risks of donation.ACKNOWLEDGMENTS
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